Lynozyfic could have an edge over rival BCMA-targeting bispecifics.
ApexOnco Front Page
Recent articles
Zegfrovy is approved in a best-case setting, but Dizal has no US presence.
The conjugates SYS6005 and TQB2101 feature among first-in-human study entrants.
Imfinzi hits on disease-free survival, but BCG won't be displaced.
The group’s latest update focused on new data with the KRAS G12C inhibitor elironrasib.
TAK-280 is among the group's discarded projects, although it’s a T-cell engager, not an ADC.
Meanwhile, Exelixis and AstraZeneca continue to invest in pivotal trials of blockbuster follow-ons.
Final survival analysis draws a blank, and Lantheus throws in the towel.
